Dinutuximab (Unituxin) — CPB 0895 | AETNA Coverage Update

Aetna modified CPB 0895 for dinutuximab (Unituxin), effective January 5, 2026. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its coverage policy for dinutuximab (Unituxin) under CPB 0895 in the Aetna dinutuximab coverage policy, adding detailed criteria for three distinct treatment scenarios in pediatric neuroblastoma. The policy governs administration claims billed under CPT codes 96365, 96366, and the 96401–96450 chemotherapy administration series, alongside HCPCS codes J2820 (sargramostim), J9015 (aldesleukin), and J9328 (temozolomide). If your team bills for pediatric oncology infusions or chemoimmunotherapy regimens, this update directly shapes what you can get paid for.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Dinutuximab (Unituxin) — CPB 0895
Policy Code	CPB 0895
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Pediatric Oncology, Hematology/Oncology, Infusion Therapy, Hospital Outpatient
Key Action	Confirm the specific neuroblastoma treatment scenario (induction, consolidation, or post-consolidation) in your prior auth request and clinical documentation before submitting claims

---

Aetna Dinutuximab Coverage Criteria and Medical Necessity Requirements 2026

The real issue with CPB 0895 is that it's not one coverage policy — it's three. Aetna separates medical necessity criteria based on where the patient is in their treatment course. Get the scenario wrong in your prior authorization request and you'll get a denial even if the drug is clinically appropriate.

Note: Prior authorization requirements are determined by Aetna's administrative processes, not stated in this coverage policy. Confirm PA requirements directly with Aetna before submitting.

Scenario 1: Standard High-Risk Neuroblastoma (Post-Consolidation Immunotherapy)

Aetna considers dinutuximab medically necessary in combination with GM-CSF (sargramostim, billed as J2820), interleukin-2 (aldesleukin, billed as J9015), and 13-cis-retinoic acid (isotretinoin) when all of the following are true:

Every one of those four criteria must be met. Missing documentation on even one — particularly the autologous stem cell transplant or the radiation therapy — will trigger a claim denial.

Scenario 2: Chemoimmunotherapy for High-Risk Disease with Inadequate Response or Progression

This is the newer pathway. Aetna covers dinutuximab as chemoimmunotherapy in combination with temozolomide (J9328), irinotecan, and sargramostim (J2820) for members under 21 when either of these conditions applies:

#	Covered Indication Copy
1	Following induction for high-risk disease with a minor response, stable disease (as bridging therapy to standard consolidation), or progressive disease
2	For progressive disease following consolidation for high-risk disease

This scenario specifically addresses patients who didn't respond well enough to induction, or who progressed after consolidation. The combination with temozolomide and irinotecan is a separate clinical protocol from Scenario 1. Document the response status clearly — "minor response," "stable disease," or "progressive disease" — using exact ICD-10 codes tied to neuroblastoma diagnosis.

Scenario 3: Post-Consolidation Therapy with Sargramostim and Isotretinoin

Aetna also covers dinutuximab in combination with sargramostim (J2820) and isotretinoin for post-consolidation therapy. This applies when the member is under 21, has completed consolidation for high-risk disease, and has had a full disease evaluation showing no disease progression.

The "no disease progression" requirement is the gate here. A full disease evaluation must be documented before this pathway is approved.

Continuation of Therapy

Aetna allows up to a maximum of five cycles. Continuation approval requires no evidence of unacceptable toxicity and no disease progression on the current regimen. Build this documentation requirement into your reauthorization workflow — don't wait until cycle four to pull the records together.

---

Aetna Dinutuximab Exclusions and Non-Covered Indications

Aetna's position is explicit: all indications for dinutuximab outside the three neuroblastoma scenarios above are considered experimental, investigational, or unproven.

There are no off-label pathways listed. There is no compassionate use carve-out in this coverage policy. If a patient doesn't fit one of the three defined neuroblastoma criteria sets, Aetna won't pay.

This is a high-stakes exclusion. Dinutuximab is a high-cost regimen. A denial on a multi-cycle treatment course is a significant reimbursement loss. Verify eligibility under one of the three covered scenarios before the first claim goes out.

---

Coverage Indications at a Glance

---

Aetna Dinutuximab Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Dinutuximab Under CPB 0895

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J2820	HCPCS	Injection, sargramostim (GM-CSF), 50 mcg
J9015	HCPCS	Injection, aldesleukin, per single use vial
J9328	HCPCS	Injection, temozolomide, 1 mg

Irinotecan: No specific HCPCS code is listed for irinotecan in this policy. Confirm the appropriate billing mechanism for irinotecan directly with Aetna or your billing consultant before submitting claims for Scenario 2 regimens.

Key ICD-10-CM Diagnosis Codes

The policy lists 188 ICD-10-CM codes. The full 188-code list should be pulled directly from the Aetna CPB 0895 source policy. No specific neuroblastoma ICD-10 codes can be confirmed from the data provided here.

The following C34.x codes appear in the policy data provided. Use the source policy to confirm the complete and accurate code list before finalizing your charge capture.

Pull the complete 188-code list from the full CPB 0895 policy at the Aetna source before finalizing your charge capture. The ICD-10 codes in the policy data provided here are a subset. Review the full list before January 5, 2026.

---